Revenue
2020
2021
2022
2023
2024
2025
Schott Pharma AG & CO KGaA (1SXP)
Price€25.20Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | €986.2M | €957.1M | €898.6M | €821.1M | €648.7M | €584.2M |
| Gross profit | €332.5M | €322.6M | €316.5M | €296.4M | €226.2M | €196.0M |
| Gross margin | 33.71% | 33.71% | 35.22% | 36.10% | 34.87% | 33.55% |
| Research & development | €27.9M | €24.3M | €26.8M | €23.5M | N/A | N/A |
| Operating expenses | €131.6M | €130.0M | €124.1M | €146.1M | €112.2M | €103.3M |
| Operating income | €200.8M | €192.6M | €192.4M | €150.4M | €114.0M | €92.7M |
| Operating margin | 20.36% | 20.12% | 21.41% | 18.31% | 17.57% | 15.86% |
| EBITDA | €287.2M | €262.4M | €244.9M | €216.3M | N/A | N/A |
| EBITDA margin | 29.12% | 27.42% | 27.25% | 26.35% | N/A | N/A |
| Net income | €147.0M | €150.3M | €151.9M | €125.8M | €101.2M | €77.6M |
| Net profit margin | 14.90% | 15.71% | 16.91% | 15.33% | 15.60% | 13.29% |
| Basic EPSper basic share | €0.97 | €0.99 | €1.01 | €0.83 | €0.67 | €0.51 |
| Diluted EPSper diluted share | €0.97 | €0.99 | €1.01 | €0.83 | €0.67 | €0.51 |
Owners
Reported major voting-rights holders
5.01%of voting rights
T. Rowe Price Group, Inc.Notified Oct 29, 2025
View holders
| Holder | Voting rights |
|---|---|
| 5.01%Oct 29, 2025 · 7.55M votes | |
| 2.90%Sep 24, 2025 · 4.37M votes | |
| 2.90%Sep 24, 2025 · 4.37M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Issuer voting-rights announcement via EQS ↗Updated Oct 21, 2026